Last updated on September 2018

COM701 in Subjects With Advanced Solid Tumors


Brief description of study

This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with a programmed cell death protein 1 (PD-1) inhibitor.

Detailed Study Description

This Phase 1 study evaluates the safety, tolerability, Pharmacokinetics (PK) and preliminary clinical activity of COM701 an inhibitor of poliovirus receptor related immunoglobulin domain containing (PVRIG) as monotherapy and in combination with a PD-1 inhibitor in subjects with advanced solid tumors. Cohort expansion in subjects with the following select tumor types (Non-Small cell lung cancer (NSCLC), Ovarian, Breast (including Triple negative breast cancer (TNBC) and Endometrial cancer) evaluating COM701 monotherapy and in combination with a PD-1 inhibitor will be explored.

Clinical Study Identifier: NCT03667716

Contact Investigators or Research Sites near you

Start Over

COM701 Study Director

The University of Tennessee WEST Cancer Center.
Memphis, TN United States
  Connect »

COM701 Study Director

Sarah Cannon Cancer Institute.
Nashville, TN United States
  Connect »

COM701 Study Director

The START Center for Cancer Care.
San Antonio, TX United States
  Connect »